A recent study published in Nature Communications by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) and collaborators evaluated a replicating RNA (repRNA) vaccine ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

SAN DIEGO, January 10, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

The material developed by NIST includes three segments of RNA corresponding to certain proteins of the H5N1 virus—the hemagglutinin, neuraminidase and matrix proteins. Most H5N1 tests rely on the ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company ... also known as LUNAR-H5N1, for active immunization to prevent ...

Consumers are clear in this new survey that they do not want to consume cow’s milk affected by bird flu virus, even if the ...

Recent history makes clear that microbiological disasters can strike anytime. But a longer history should remind us of the ...